Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
An erratum to this article was published (J Rheumatol, 1 Jun 2026 ↗)
Main finding · ICI-IAResult — go to the resultHazard ratio 1.24Authors' conclusion
CT-derived hip OA was not significantly associated with development of ICI-IA in this cohort of patients with lung cancer. ICI-IA was associated with decreased mortality.
Study context
- Population
- Patients treated for thoracic cancer with immune checkpoint inhibitor (ICI) therapy and with computed tomography (CT) of the abdomen/pelvis within 1 month of ICI start
- Participants
- 309 patients
- Exposure
- Hip osteoarthritis (OA) vs no hip OA
- Hip OAn = 103
- Outcome
- Development of ICI-induced inflammatory arthritis (ICI-IA)
Methodological detailschart review, Kaplan-Meier curves, Cox proportional hazards
- Chart review
- Kaplan-Meier curves
- Cox proportional hazards
Main finding
ICI-IA
Hazard ratio
1.24
P = 0.55
As reported in the abstract
- Overall cumulative incidence of ICI-IA
- 54.8/1000 person-years
Observational data: associations, not effects.
Further findings
ICI-IA by BMI (higher BMI)
- Higher BMI associated with significantly lower hazard for ICI-IA, HR (P = 0.049)
- 0.93
Overall survival
- ICI-IA, HR (P = 0.02)
- 0.59
- Higher BMI, HR (P = 0.03)
- 0.97
- Higher cancer stage, HR (P < 0.01)
- 1.60
- Survival did not differ by hip OA status
- Multivariable analysis
Original publication
Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis. J Rheumatol. Published 15 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →